LEIDEN, THE NETHERLANDS--(Marketwire - June 19, 2012) - Biotech company Pharming Group NV
("Pharming" or "the Company") (NYSE Euronext: PHARM) today announces that
its
Chief Medical Officer Dr. Rienk Pijpstra has resigned from the Board of
Management, and will leave the company on September 1st.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of
unmet
medical needs. RUCONEST® (RHUCIN® in non-European territories) is
a recombinant
human C1 inhibitor approved for the treatment of angioedema attacks in
patients
with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein, and
is
distributed in the EU by Swedish Orphan Biovitrum (OMX: SOBI). RHUCIN®
is
partnered with Santarus, Inc (NASDAQ: SNTS) in North America where the drug
is
undergoing Phase III clinical development. The product is also being
evaluated
for follow-on indications in the areas of transplantation and reperfusion
injury. The advanced technologies of the Company include innovative and
validated platforms for the production of protein therapeutics, technology
and
processes for the purification and formulation of these products. A
feasibility
study, using the validated transgenic rabbit platform, aimed at the
development
of recombinant Factor VIII for the treatment of Haemophilia A is underway
with
partner, Renova Life, Inc. Additional information is available on the
Pharming
website, www.pharming.com. To download the Pharming Group Investor
Relations
App, click here.
This press release contains forward looking statements that involve known
and
unknown risks, uncertainties and other factors, which may cause the actual
results, performance or achievements of the Company to be materially
different
from the results, performance or achievements expressed or implied by these
forward looking statements.
Press release (PDF):
http://hugin.info/132866/R/1620471/517717.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Pharming Group N.V. via Thomson Reuters ONE
[HUG#1620471]
